Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PBM Catalyst Timeline
Dated clinical, regulatory and corporate events for Psyence Biomedical Ltd.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Psyence Biomedical Ltd.
Upcoming catalysts 2
Event history 50
Past FDA Catalysts and PDUFA Decisions
How PBM actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Drug Pipeline Intelligence
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Psilocybin therapy Small MoleculesNCT07072728 | Adjustment Disorder | Phase 2 | RECRUITING | 87 | Dec 30, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every PBM program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| No insider trades match the selected filters. | |||||
Hedge Fund 13F Activity
Hedge Funds invested in PBM
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in PBM for Q3 2026. | ||||
Ownership Trends
PBM Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How PBM ranks across every disease it competes in
PBM News
Psyence BioMed Completes PsyLabs Investment as Ibogaine Milestones Are Met
Psyence BioMed invested $2.6 million in PsyLabs after meeting two milestones. The company completed ibogaine regulatory documentation and signed a cGMP manufacturing deal with Benuvia. This investment raises Psyence’s stake in PsyLabs to 43.37 percent. The move supports the firm’s U.S. ibogaine development program.
Read more →Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade Ibogaine
Psyence BioMed's subsidiary, Texas Ibogaine Research Corporation, has partnered with Benuvia Operations to manufacture pharmaceutical-grade ibogaine in the U.S. This collaboration aims to establish a compliant manufacturing pathway under DEA regulations. The partnership is part of Psyence's strategy to support clinical programs for mental health and substance use disorders, leveraging Benuvia's extensive manufacturing capabilities.
Read more →Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation
Psyence BioMed's subsidiary, Texas Ibogaine Research Corporation, has secured an exclusive U.S. license for pharmaceutical-grade ibogaine from PsyLabs. This agreement provides TIRC with rights to develop and distribute ibogaine, contingent on a definitive agreement by November 30, 2026. The collaboration aims to expedite the development of ibogaine drug candidates to meet mental health needs.
Read more →Psyence BioMed Announces Strategic Ibogaine Investment
Psyence BioMed has announced a strategic investment of up to $5 million in PsyLabs, along with a value-matched share exchange valued at approximately $9 million. This initiative aims to support the development of pharmaceutical-grade ibogaine for a potential clinical trial targeting Opioid Use Disorder in Texas. The establishment of the Texas Ibogaine Research Corporation will facilitate regulatory and clinical activities for the U.S. program.
Read more →Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine Development
Psyence BioMed has established the Texas Ibogaine Research Corporation to coordinate U.S. development of pharmaceutical-grade ibogaine. This entity aims to streamline supply, regulatory engagement, and clinical development efforts. The formation follows recent U.S. policy developments promoting ibogaine research, with plans for future licensing and regulatory activities. Jody Aufrichtig will lead TIRC as CEO.
Read more →Psyence BioMed Welcomes U.S. Administration’s Latest Action to Accelerate Ibogaine Development
Psyence BioMed has welcomed the U.S. government's announcement to accelerate ibogaine development, aligning with their pharmaceutical platform. President Trump highlighted the submission of the original ibogaine IND application by the University of Miami, which could expedite clinical research. The company is actively engaging with stakeholders to advance ibogaine's clinical development.
Read more →Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing
Psyence BioMed Ltd. announced a strategic engagement initiative in the U.S. to promote GMP ibogaine research and manufacturing. The company's leadership will meet with key stakeholders to discuss regulatory considerations and scientific infrastructure. This initiative follows recent U.S. policy changes supporting psychedelic research, and Psyence aims to educate on compliant ibogaine production.
Read more →Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder
Psyence Biomedical Ltd. has commenced patient dosing in its Phase IIb clinical trial assessing NPX-5, a psilocybin treatment for Adjustment Disorder in cancer patients receiving palliative care. This trial marks the first significant human evaluation of NPX-5 and aims to evaluate its safety and efficacy across multiple sites in Australia. The company seeks to generate critical clinical data to inform future development and regulatory pathways while addressing a significant psychological need in this patient population.
Read more →Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source
Psyence Biomedical Ltd. has established itself as the only licensed supplier of pharmaceutical-grade ibogaine by developing a vertically integrated platform for sourcing, manufacturing, and supplying ibogaine. The company has positioned itself to support the scientific and clinical research community as regulatory interest in ibogaine grows. By securing direct access to the natural source of ibogaine in Africa and maintaining a GMP-compliant inventory, Psyence aims to address the existing supply gaps in the market. Their capabilities will enable continued research and potential commercialization of ibogaine-based therapies.
Read more →Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine
Psyence BioMed has welcomed reports of an upcoming U.S. executive order aimed at evaluating the safety and therapeutic potential of ibogaine, a compound thought to aid in treating PTSD and addiction. The move is seen as a necessary step toward regulated research in areas with limited treatment options. The company emphasizes the importance of controlled clinical research and has also established a GMP-compliant manufacturing presence for ibogaine. With increased interest in ibogaine, Psyence aims to support scientific progress through ethical sourcing and a robust supply chain.
Read more →Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities
Psyence Biomedical Ltd. announced the expansion of its Australian clinical site network from three to five sites, including the addition of Ramsay Health Care and NeuroCentrix. This expansion is aimed at strengthening recruitment and accelerating enrollment for its ongoing Phase IIb clinical trial evaluating natural psilocybin for treating Adjustment Disorder in cancer patients. The company's move is expected to broaden its operational efficiency and support patient dosing. CEO Jody Aufrichtig emphasized the importance of this growth for generating meaningful clinical data.
Read more →Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone
Psyence BioMed has advanced its vertically integrated pharmaceutical platform through a strategic investment in PsyLabs, enhancing its manufacturing and supply chain capabilities. The company has achieved a key milestone by exporting its first clinical trial product to Australia. Psyence BioMed emphasizes disciplined capital allocation and aims for sustainable growth while navigating the evolving psychedelic therapeutics market.
Read more →Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial
Psyence BioMed has successfully exported its GMP-manufactured psilocybin product NPX-5 to Australia for a Phase IIb clinical trial. This trial aims to evaluate the efficacy of natural psilocybin in treating Adjustment Disorder in cancer patients. The company emphasizes its commitment to quality and regulatory compliance while pioneering the use of nature-derived psychedelics in mental health care.
Read more →Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment
Psyence Biomedical Ltd. (Nasdaq: PBM) announced that PsyLabs exercised its put option, enabling a strategic equity investment where Psyence will acquire shares in PsyLabs. This exercise aims to strengthen the collaboration between the two companies, enhancing Psyence's access to high-quality psychedelic manufacturing resources. The transaction involves a Share-for-Share Exchange, resulting in PsyLabs obtaining roughly 49.98% ownership of Psyence's common shares. While this aligns with Psyence's long-term growth objectives, it poses risks of dilution for existing shareholders and significant influence over governance.
Read more →Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders
Psyence Biomedical Ltd. announced the results of its Annual and Special Meeting of Shareholders held on February 12, 2026. Shareholders approved all proposed business matters, including the election of directors and the appointment of auditors. Additionally, they authorized the board to consolidate shares at a ratio of up to 250:1, pending regulatory approvals.
Read more →Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway
Psyence Biomedical Ltd. has ratified a put option agreement with PsyLabs, allowing for a potential equity investment in the company. This agreement is part of a strategic relationship that enhances Psyence's access to PsyLabs' advanced manufacturing capabilities for pharmaceutical-grade psychedelics. The partnership aims to streamline Psyence's commercialization efforts and assures a reliable supply of these compounds for clinical and commercial programs. However, the success of this agreement hinges on PsyLabs' continued operational and regulatory compliance.
Read more →BioMed Approves a Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway Put Option Agreement positions Psyence BioMed for potential significant future equity participation in one of the world's most
Psyence BioMed has ratified a Put Option Agreement with PsyLabs, which allows PsyLabs to require Psyence to make an equity investment in exchange for access to its manufacturing capabilities. This agreement is designed to secure a reliable supply of pharmaceutical-grade psychedelics as Psyence advances its commercialization strategy. The partnership positions Psyence to mitigate risks related to regulatory and supply-chain challenges, enabling more secure planning for future clinical programs. The arrangement also preserves the company's financial flexibility while aiming to strengthen their product pipeline.
Read more →Psyence BioMed Announces Settlement of Shareholder Litigation
Psyence Biomedical Ltd. has announced a settlement agreement to resolve a direct shareholder claim made by KAOS Capital Ltd. The settlement includes a payment of $1.5 million to KAOS and a retraction of the allegations made against the company. While the company denies any wrongdoing, it opted for the settlement to avoid further litigation and associated costs.
Read more →Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split
Psyence Biomedical Ltd. has announced the effective date for its 1-for-6.25 reverse stock split, which will take effect on February 2, 2026. This decision follows earlier Board approvals for share consolidations and aims to enhance the company's trading performance. The total number of issued shares will decrease significantly, and there may be some impact on shareholders who hold shares through brokers. The company continues to focus on psychedelic-based therapeutics and its Nasdaq listing under the symbol 'PBM'.
Read more →